Development and validation of a 32-gene prognostic index for prostate cancer progression

Proceedings of the National Academy of Sciences of the United States of America

Volumn 110, Issue 15, 2013, Pages 6121-6126

  Wu, Chin Lee ^a   Schroeder, Brock E ^b   Ma, Xiao Jun ^b   Cutie, Christopher J ^a   Wu, Shulin ^a   Salunga, Ranelle ^b   Zhang, Yi ^b   Kattan, Michael W ^c   Schnabel, Catherine A ^b   Erlander, Mark G ^b   Scott McDougal, W ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b BioTheranostics Inc   (United States)

^c LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; ARTICLE; CANCER GROWTH; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER STAGING; CLINICAL ARTICLE; FOLLOW UP; GENE EXPRESSION; GLEASON SCORE; HUMAN; HUMAN TISSUE; MALE; METASTASIS; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROSTATE; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY;

ADULT; AGED; BIOPSY; COHORT STUDIES; DISEASE PROGRESSION; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSTATE; PROSTATIC NEOPLASMS; REAL-TIME POLYMERASE CHAIN REACTION;

EID: 84876063784     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1215870110     Document Type: Article

References (34)

1. American Cancer Society (2010) Cancer Facts and Figures 2010 (American Cancer Society, Atlanta).
2. Agency for Healthcare Research and Quality (2011) HCUPnet, Healthcare Cost and Utilization Project. Available at http://hcupnet.ahrq.gov. Accessed May 13, 2011.
3. Amling CL, et al. (2000) Long-term hazard of progression after radical prostatectomy for clinically localized prostate cancer: Continued risk of biochemical failure after 5 years. J Urol 164(1):101-105.
4. Han M, Partin AW, Pound CR, Epstein JI, Walsh PC (2001) Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience. Urol Clin North Am 28(3):555-565.
5. Hull GW, et al. (2002) Cancer control with radical prostatectomy alone in 1, 000 consecutive patients. J Urol 167(2 Pt 1):528-534.
6. Bolla M, et al.; European Organization for Research and Treatment of Cancer (2005) Postoperative radiotherapy after radical prostatectomy: A randomised controlled trial (EORTC trial 22911). Lancet 366(9485):572-578.
7. Thompson IM, Jr., et al. (2006) Adjuvant radiotherapy for pathologically advanced prostate cancer: A randomized clinical trial. JAMA 296(19):2329-2335.
8. Wiegel T, et al. (2009) Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95. J Clin Oncol 27(18):2924-2930.
9. Thompson IM, et al. (2009) Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: Long-term followup of a randomized clinical trial. J Urol 181(3):956-962.
10. Psutka SP, et al. (2011) Men with organ-confined prostate cancer and positive surgical margins develop biochemical failure at a similar rate to men with extracapsular extension. Urology 78(1):121-125.
11. Freedland SJ, Partin AW, Epstein JI, Walsh PC (2004) Biochemical failure after radical prostatectomy in men with pathologic organ-confined disease: pT2a versus pT2b. Cancer 100(8):1646-1649.
12. Kattan MW, Eastham JA, Stapleton AM, Wheeler TM, Scardino PT (1998) A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J Natl Cancer Inst 90(10):766-771.
13. Greene KL, et al. (2004) Validation of the Kattan preoperative nomogram for prostate cancer recurrence using a community based cohort: Results from cancer of the prostate strategic urological research endeavor (capsure). J Urol 171(6 Pt 1):2255-2259.
14. Makarov DV, et al. (2007) Updated nomogram to predict pathologic stage of prostate cancer given prostate-specific antigen level, clinical stage, and biopsy Gleason score (Partin tables) based on cases from 2000 to 2005. Urology 69(6):1095-1101.
15. Stephenson AJ, et al. (2005) Postoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. J Clin Oncol 23(28):7005-7012.
16. Paik S, et al. (2004) A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 351(27):2817-2826.
17. Dowsett M, et al. (2010) Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: A TransATAC study. J Clin Oncol 28(11):1829-1834.
18. Albain KS, et al.; Breast Cancer Intergroup of North America (2010) Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: A retrospective analysis of a randomised trial. Lancet Oncol 11(1):55-65.
19. Kattan MW, Wheeler TM, Scardino PT (1999) Postoperative nomogram for disease recurrence after radical prostatectomy for prostate cancer. J Clin Oncol 17(5):1499-1507.
20. Kattan MW, et al. (2009) Preoperative and postoperative nomograms incorporating surgeon experience for clinically localized prostate cancer. Cancer 115(5):1005-1010.
21. Mohler J, et al. (2010) NCCN clinical practice guidelines in oncology: Prostate cancer. J Natl Compr Canc Netw 8(2):162-200.
22. Draisma G, et al. (2009) Lead time and overdiagnosis in prostate-specific antigen screening: Importance of methods and context. J Natl Cancer Inst 101(6):374-383.
23. Schröder FH, et al.; ERSPC Investigators (2009) Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 360(13):1320-1328.
24. Stephenson AJ, et al. (2005) Integration of gene expression profiling and clinical variables to predict prostate carcinoma recurrence after radical prostatectomy. Cancer 104(2):290-298.
25. Talantov D, et al. (2010) Gene based prediction of clinically localized prostate cancer progression after radical prostatectomy. J Urol 184(4):1521-1528.
26. Cuzick J, et al.; Transatlantic Prostate Group (2011) Prognostic value of an RNA expression signature derived from cell cycle proliferation genes in patients with prostate cancer: A retrospective study. Lancet Oncol 12(3):245-255.
27. Sboner A, et al. (2010) Molecular sampling of prostate cancer: A dilemma for predicting disease progression. BMC Med Genomics 3:8.
28. Taylor BS, et al. (2010) Integrative genomic profiling of human prostate cancer. Cancer Cell 18(1):11-22.
29. Epstein JI, Allsbrook WC, Jr., Amin MB, Egevad LL; ISUP Grading Committee (2005) The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma. Am J Surg Pathol 29(9):1228-1242.
30. Fan JB, et al. (2004) A versatile assay for high-throughput gene expression profiling on universal array matrices. Genome Res 14(5):878-885.
31. Bibikova M, et al. (2004) Quantitative gene expression profiling in formalinfixed, paraffin-embedded tissues using universal bead arrays. Am J Pathol 165(5):1799-1807.
32. Gray RJ (1988) A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 16(3):1141-1154.
33. Little R J A (1988) Missing data adjustments in large surveys. J Bus Econ Stat 6:287-296.
34. Van Buuren S, Groothuis-Oudshoorn K (2011) MICE: Multivariate imputation by chained equations in R. J Stat Softw 45(3):1-67.